Last reviewed · How we verify

crystalloid cardioplegia solution

Baskent University · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

crystalloid cardioplegia solution is a Small molecule drug developed by Baskent University. It is currently FDA-approved.

Crystalloid cardioplegia solution is used in the treatment of various heart conditions, including aortic valve disease, mitral valve disease, and coronary artery disease. It is a type of oligosaccharide-based solution, which is also known as an anticoagulant heparin solution.

At a glance

Generic namecrystalloid cardioplegia solution
SponsorBaskent University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about crystalloid cardioplegia solution

What is crystalloid cardioplegia solution?

crystalloid cardioplegia solution is a Small molecule drug developed by Baskent University.

Who makes crystalloid cardioplegia solution?

crystalloid cardioplegia solution is developed and marketed by Baskent University (see full Baskent University pipeline at /company/baskent-university).

What development phase is crystalloid cardioplegia solution in?

crystalloid cardioplegia solution is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing